Shanghai Junshi Biosciences Co Ltd
688180.SS- Latest Trade
- trading lower48.6CNY
- -0.6
- 1.22%
- As of May 28 2023. Values delayed up to 15 minutes
- Today's Range
- 48.30 - 49.20
- 52 Week Range
- 44.48 - 92.86
- Previous Close
- 49.20
- Open
- 49.20
- Volume
- 2,505,191.00
- 3 Month Average Trading Volume
- 95.99
- Shares Out (Mil)
- 985.69
- Market Cap
- 42,679.16
- Forward P/E
- -27.77
- Dividend Yield
- 0.00
Key Statistics
1.50 mean rating - 8 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 39.55
- Price To Book (Quarterly)
- 5.35
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 15.55
- Long Term Debt/Equity (Quarterly)
- 10.54
- Return On Investment (TTM)
- -30.24
- Return On Equity (TTM)
- -24.28
2021 (millions USD)
About Shanghai Junshi Biosciences Co Ltd (688180.SS)
Company Information
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
Address
16F, Building 7, No. 6, Lane 100 Pingjiaqiao Road, Pudong New AreaSHANGHAI, SHA
201203
China
Industry
Biotechnology & Drugs
Executive Leadership
- Jun Xiong
- Executive Chairman of the Board
- Cong Li
- Co-Chief Executive Officer, Executive Director
- Baohong Xu
- Chief Financial Officer
- Ning Li
- General Manager, Executive Director
- Sheng Yao
- Deputy General Manager, Executive Director
- Zhuobing Zhang
- Deputy General Manager, Executive Director
- Jianjun Zou
- Deputy General Manager, President, Global R&D, Executive Director
- Gang Wang
- Deputy General Manager, Chief Quality Officer
- Hui Feng
- Executive Director
- Yingge Chen
- Secretary of the Board, Joint Company Secretary
- Yi Tang
- Non-Executive Director
- Hai Wu
- Non-Executive Director
- Lieping Chen
- Independent Non-Executive Director
- Xiaoyuan Feng
- Independent Non-Executive Director
- Roy Steven Herbst
- Independent Non-Executive Director
- Zhi Qian
- Independent Non-Executive Director
- Chun Zhang
- Independent Non-Executive Director
Latest News
- BusinessChina Junshi's potential COVID drug shows promise in small trial
An antiviral oral drug being co-developed by Shanghai Junshi Biosciences' subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in COVID-19 patients, according to a small clinical trial.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,944.30 | -- |
| Copper | 706.90 | 1.77% |
| Brent Crude Oil | 76.95 | -- |
| CBOT Soybeans | 1,337.25 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,205.45 | 1.30% |
| Euro STOXX 50 | 4,337.50 | 1.59% |
| FTSE 100 | 7,627.20 | 0.74% |
| Nikkei 225 | 30,916.31 | 0.37% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes